Sofosbuvir (Synonyms: 索非布韦; GS-7977; PSI-7977)

目录号: HY-15005 纯度: 99.97%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Sofosbuvir (GS-7977) 是 HCV RNA复制抑制剂，EC₅₀ 为 92 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sofosbuvir Chemical Structure

CAS No. : 1190307-88-0

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥431	In-stock
1 mg	￥185	In-stock
5 mg	￥370	In-stock
10 mg	￥500	In-stock
50 mg	￥640	In-stock
100 mg	￥770	In-stock
500 mg	￥1100	In-stock
1 g	￥1400	In-stock
5 g		询价
10 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Sofosbuvir:

MCE 顾客使用本产品发表的 112 篇科研文献

: Sofosbuvir purchased from MCE. Usage Cited in: Eur J Med Chem. 2018 Jan 1:143:1053-1065. [Abstract]; Huh7.5 cells are infected with HCV and simultaneously treated with 7f (10 μM) or DAA (0.04 μM Simeprevir, 0.08 μM Sofosbuvir, or 16 pM Daclatasvir) or 7f plus DAA.

: Sofosbuvir purchased from MCE. Usage Cited in: Eur J Med Chem. 2018 Jan 1:143:1053-1065. [Abstract]; GS4.3 cells are treated with 7f (20 μM), or Telaprevir (0.5μM), Sofosbuvir (0.8 μM), Daclatasvir (0.15 μM) or solvent control for 6 days.

: Sofosbuvir purchased from MCE. Usage Cited in: Biomed Res Int. 2017:2017:1236801. [Abstract]; Huh7.5 (HCV+) cells are treated with 1 μM of Sofosbuvir or solvent control. At 24 hours, the cells are washed and continuously incubated with fresh culture media containing drugs again for 48 hours. The cultural supernatants are then harvested and directly incubated to naïve Huh7.5 cells. After been passaged 1~3 times, the newly infected cells are treated with 1 μM of Sofosbuvir for 72 hours. Intracellular proteins are extracted and detected with WB.

: Sofosbuvir purchased from MCE. Usage Cited in: J Med Chem. 2016 Nov 23;59(22):10268-10284. [Abstract]; Huh7.5 cells are infected with HCV (45 IU/cell) and simultaneously treated with Simeprevir (A, 0.025 μM), Sofosbuvir (B, 0.1 μM), or Daclatasvir (C, 16 pM) alone or with 1 (6.25 μM).

Sofosbuvir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC₅₀ of 92 nM^[1].

IC₅₀ & Target

EC50: 92±5 nM (HCV)^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	> 100 μM Compound: 1; SOF	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay	[PMID: 28595015]
CCRF-CEM	CC₅₀	> 100 μM Compound: SOF	Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay	[PMID: 30653317]
CCRF-CEM	CC₅₀	> 100 μM Compound: SOF; 1	Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method	[PMID: 30655167]
CCRF-CEM	CC₅₀	> 100 μM Compound: Sofosbuvir	Cytotoxicity against human CEM cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay Cytotoxicity against human CEM cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay	[PMID: 29066308]
Calu-3	CC₅₀	512 μM Compound: Sofosbuvir	Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition incubated for 4 hrs by XTT assay Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition incubated for 4 hrs by XTT assay	[PMID: 36965227]
HK-2	CC₅₀	> 300 μM Compound: SOF	Nephrotoxicity in human HK2 cells after 72 hrs by Hoechst 33342/HCS live/dead green dye-based assay Nephrotoxicity in human HK2 cells after 72 hrs by Hoechst 33342/HCS live/dead green dye-based assay	[PMID: 30653317]
HepG2	CC₅₀	> 50 μM Compound: Sofosbuvir	Cytotoxicity against human HepG2 cells after 96 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells after 96 hrs by CCK-8 assay	[PMID: 29801997]
HepG2	IC₅₀	45 μM Compound: SOF	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	[PMID: 30653317]
HepG2	IC₅₀	> 50 μM Compound: 1; SOF	Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method	[PMID: 28595015]
HepG2	IC₅₀	> 50 μM Compound: 1; SOF	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method	[PMID: 28595015]
HepG2	IC₅₀	> 50 μM Compound: SOF	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	[PMID: 30653317]
HepaRG	CC₅₀	44 μM Compound: SOF	Cytotoxicity in human HepaRG cells assessed as reduction in cell viability incubated for 14 days by CellTiter-Glo assay Cytotoxicity in human HepaRG cells assessed as reduction in cell viability incubated for 14 days by CellTiter-Glo assay	[PMID: 30653317]
Hepatocyte	CC₅₀	> 300 μM Compound: SOF	Cytotoxicity against human primary hepatocytes assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human primary hepatocytes assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30653317]
Huh-7	CC₅₀	200 μM Compound: Sofosbuvir	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 32435411]
Huh-7	CC₅₀	200 μM Compound: Sofosbuvir	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay	[PMID: 34273661]
Huh-7	CC₅₀	> 10 μM Compound: 1; SOF	Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay	[PMID: 28595015]
Huh-7	CC₅₀	> 10 μM Compound: Sofosbuvir	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by MTT assay	[PMID: 29066308]
Huh-7	CC₅₀	> 100 μM Compound: PSI-7977	Cytotoxicity against human Huh7.5.1 cells after 48 hrs by luciferase reporter gene assay Cytotoxicity against human Huh7.5.1 cells after 48 hrs by luciferase reporter gene assay	[PMID: 27994763]
Huh-7	CC₅₀	> 100 μM Compound: SOF	Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay	[PMID: 30653317]
Huh-7	CC₅₀	> 100 μM Compound: SOF	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by viral-Tox-glo assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by viral-Tox-glo assay	[PMID: 37159959]
Huh-7	CC₅₀	> 100 μM Compound: SOF; 1	Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels after 5 days by RT-PCR analysis Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels after 5 days by RT-PCR analysis	[PMID: 30655167]
Huh-7	CC₅₀	> 1000 μM Compound: 17	Cytotoxicity against human HuH7 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human HuH7 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 29172078]
Huh-7	CC₅₀	> 20 μM Compound: Sofosbuvir	Cytotoxicity against human HuH7 cells infected with HCV genotype 1b replicon after 72 hrs by CellTiter-Fluor reagent based fluorescence assay Cytotoxicity against human HuH7 cells infected with HCV genotype 1b replicon after 72 hrs by CellTiter-Fluor reagent based fluorescence assay	[PMID: 30683552]
Huh-7	EC₅₀	0.053 μM Compound: 1	Antiviral activity against HCV genotype 1b Con1 over expressing CES1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay Antiviral activity against HCV genotype 1b Con1 over expressing CES1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	[PMID: 31740203]
Huh-7	EC₅₀	0.062 μM Compound: 1	Antiviral activity against HCV genotype 1b Con1 expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 1b Con1 expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.0751 μM Compound: 1	Antiviral activity against HCV genotype 3a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 3a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.0785 μM Compound: 1	Antiviral activity against HCV genotype 4a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 4a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.0867 μM Compound: 1	Antiviral activity against HCV genotype 6a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 6a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.12 μM Compound: PSI-7977	Antiviral activity against HCV JFH-1 infected in human HuH7.5.1 cells after 48 hrs by luciferase reporter gene assay Antiviral activity against HCV JFH-1 infected in human HuH7.5.1 cells after 48 hrs by luciferase reporter gene assay	[PMID: 27994763]
Huh-7	EC₅₀	0.155 μM Compound: 1	Antiviral activity against HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay Antiviral activity against HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	[PMID: 31740203]
Huh-7	EC₅₀	0.155 μM Compound: Sofosbuvir	Inhibition of NS5B polymerase in HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay Inhibition of NS5B polymerase in HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	[PMID: 32046903]
Huh-7	EC₅₀	0.188 μM Compound: 1	Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	[PMID: 31740203]
Huh-7	EC₅₀	0.23 μM Compound: Sofosbuvir	Inhibition of NS5B polymerase in HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay Inhibition of NS5B polymerase in HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	[PMID: 32046903]
Huh-7	EC₅₀	0.254 μM Compound: 25	Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay	[PMID: 24345201]
Huh-7	EC₅₀	0.3301 μM Compound: 1	Antiviral activity against HCV genotype 3a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 3a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.6376 μM Compound: 1	Antiviral activity against HCV genotype 1b Con1 expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 1b Con1 expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.6813 μM Compound: 1	Antiviral activity against HCV genotype 2a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 2a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	1.002 μM Compound: 1	Antiviral activity against HCV genotype 2a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 2a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	IC₅₀	3.8 μM Compound: Sofosbuvir	Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infected and measured after 72 hrs by immunodetection assay Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infected and measured after 72 hrs by immunodetection assay	[PMID: 32435411]
Huh-7.5	CC₅₀	121.47 μM Compound: SOF	Cytotoxicity against human Huh7.5 cells carrying HCV subgenomic replicons assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human Huh7.5 cells carrying HCV subgenomic replicons assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35050619]
Huh-7.5	CC₅₀	170.85 μM Compound: SOF	Cytotoxicity against human Huh7.5 cells infected with HCVcc assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human Huh7.5 cells infected with HCVcc assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35050619]
Huh-7.5	CC₅₀	> 200 μM Compound: SOF	Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35050619]
Huh-7.5	CC₅₀	> 200 μM Compound: Sofosbuvir	Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability by CCK-8 assay Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability by CCK-8 assay	[PMID: 38561238]
PBMC	CC₅₀	> 100 μM Compound: 1; SOF	Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay	[PMID: 28595015]
PBMC	CC₅₀	> 100 μM Compound: SOF	Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay	[PMID: 30653317]
PBMC	CC₅₀	> 100 μM Compound: SOF; 1	Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method	[PMID: 30655167]
PBMC	CC₅₀	> 100 μM Compound: Sofosbuvir	Cytotoxicity against human PBMC assessed as reduction in cell viability after 6 days by trypan blue exclusion assay Cytotoxicity against human PBMC assessed as reduction in cell viability after 6 days by trypan blue exclusion assay	[PMID: 29066308]
Vero	CC₅₀	360 μM Compound: 5	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 31549836]
Vero	CC₅₀	> 100 μM Compound: 1; SOF	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay	[PMID: 28595015]
Vero	CC₅₀	> 100 μM Compound: SOF	Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay	[PMID: 30653317]
Vero	CC₅₀	> 100 μM Compound: SOF; 1	Cytotoxicity against African green monkey Vero cells after 3 days by hemocytometric method Cytotoxicity against African green monkey Vero cells after 3 days by hemocytometric method	[PMID: 30655167]
Vero	CC₅₀	> 100 μM Compound: Sofosbuvir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay	[PMID: 29066308]
Vero	EC₅₀	30.9 μM Compound: 5	Inhibition of RNA-dependent RNA polymerase in Zika virus infected in African green monkey Vero cells assessed as antiviral activity by DAPI-staining based assay Inhibition of RNA-dependent RNA polymerase in Zika virus infected in African green monkey Vero cells assessed as antiviral activity by DAPI-staining based assay	[PMID: 31549836]

体外研究
(In Vitro)

当组织蛋白酶 A (CatA) 与 Sofosbuvir 孵育 150 分钟时，Sofosbuvir 与 CatA 的催化效率约为 PSI-7976 的 30 倍^[1]。
通过使用 GT 1b (Con1)-、1a (H77)- 和 2a (JFH-1) 衍生的复制子以及含有来自 J6 GT 2a 分离株和 GT 2b 和 GT 3a 患者分离株的 NS5B 区域的 GT 1b 嵌合复制子来评估 Sofosbuvir 的基因型覆盖率，索Sofosbuvir 以相似的 EC₅₀ (在 16 和 48 nM 之间) 抑制这些复制子的复制，并且对含有 J6 NS5B 的嵌合复制子特别有效(EC₅₀=4.7 nM)。Sofosbuvir 抑制克隆 A (GT 1b) 野生型和 S282T 复制子，EC₉₀ 值分别为 0.42 μM 和 7.8 μM^[2]。
在克隆 A 复制子测定中，Sofosbuvir产生抗 HCV 活性，EC₉₀ 值为 0.42 μM^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

529.45

Formula

C₂₂H₂₉FN₃O₉P

CAS 号

1190307-88-0

性状

固体

颜色

White to off-white

中文名称

索非布韦；索氟布韦

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 50 mg/mL (94.44 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : 25 mg/mL (47.22 mM; 超声助溶 (<50°C))

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8888 mL	9.4438 mL	18.8875 mL
5 mM	0.3778 mL	1.8888 mL	3.7775 mL
10 mM	0.1889 mL	0.9444 mL	1.8888 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (3.15 mM); 澄清溶液

此方案可获得 ≥ 1.67 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (3.15 mM); 澄清溶液

此方案可获得 ≥ 1.67 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 1.67 mg/mL (3.15 mM); 澄清溶液

此方案可获得 ≥ 1.67 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 4.55 mg/mL (8.59 mM); 澄清溶液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

该产品水溶性佳，请具体参考实测水 / PBS / Saline 中的溶解度数据。

您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。

纯度 & 产品资料

纯度: 99.97%

选择批次：

Data Sheet (646 KB) SDS (393 KB)

COA (294 KB) RP-HPLC (328 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Murakami E, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem. 2010 Nov 5;285(45):34337-47. [Content Brief]

[2]. Lam AM, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68. [Content Brief]

[3]. Sofia MJ, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010 Oct 14;53(19):7202-18. [Content Brief]

[4]. Zhang X, et al. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. Eur J Med Chem. 2018 Jan 1;143:1053-1065. [Content Brief]

Cell Assay ^[1]	Clone A cells are seeded into T75 flasks at about 5×10⁶ cells/flask in Dulbecco's modified Eagle's medium (DMEM) containing 100 IU/mL Penicillin/100 μg/mL streptomycin and 10% fetal bovine serum. Similarly, human primary hepatocytes are seeded in cell plating medium into T75 flasks at about 5×10⁶ cells/flask. After overnight incubation to allow the cells to attach, cells are incubated with 50 μM PSI-7851, PSI-7976, or Sofosbuvir (PSI-7977) in fresh medium for clone A cells or in cell maintenance medium for primary hepatocytes for up to 24 h at 37°C in a 5% CO₂ atmosphere. The same procedures are applied when radiolabeled PSI-7851 is used in the study except that 1×10⁶ cells per well are seeded into a 6-well plate, and the cells are incubated with 5 μM [³H]PSI-7851. At selected times, the medium is removed, and the cell layer is washed with cold phosphate-buffered saline (PBS). After trypsinization, cells are counted and centrifuged at 1,200 rpm for 5 min. The cell pellets are suspended in 1 mL of cold 60% methanol and incubated overnight at −20°C. The samples are centrifuged at 14,000 rpm for 5 min, and the supernatants are collected and dried using a SpeedVac concentrator and stored at −20°C until they are analyzed by high performance liquid chromatography (HPLC). Residues are suspended in 100 μL of water, and 50-μL aliquots are injected into HPLC^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Murakami E, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem. 2010 Nov 5;285(45):34337-47. [Content Brief] [2]. Lam AM, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68. [Content Brief] [3]. Sofia MJ, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010 Oct 14;53(19):7202-18. [Content Brief] [4]. Zhang X, et al. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. Eur J Med Chem. 2018 Jan 1;143:1053-1065. [Content Brief]

Cell Assay
^[1]

Clone A cells are seeded into T75 flasks at about 5×10⁶ cells/flask in Dulbecco's modified Eagle's medium (DMEM) containing 100 IU/mL Penicillin/100 μg/mL streptomycin and 10% fetal bovine serum. Similarly, human primary hepatocytes are seeded in cell plating medium into T75 flasks at about 5×10⁶ cells/flask. After overnight incubation to allow the cells to attach, cells are incubated with 50 μM PSI-7851, PSI-7976, or Sofosbuvir (PSI-7977) in fresh medium for clone A cells or in cell maintenance medium for primary hepatocytes for up to 24 h at 37°C in a 5% CO₂ atmosphere. The same procedures are applied when radiolabeled PSI-7851 is used in the study except that 1×10⁶ cells per well are seeded into a 6-well plate, and the cells are incubated with 5 μM [³H]PSI-7851. At selected times, the medium is removed, and the cell layer is washed with cold phosphate-buffered saline (PBS). After trypsinization, cells are counted and centrifuged at 1,200 rpm for 5 min. The cell pellets are suspended in 1 mL of cold 60% methanol and incubated overnight at −20°C. The samples are centrifuged at 14,000 rpm for 5 min, and the supernatants are collected and dried using a SpeedVac concentrator and stored at −20°C until they are analyzed by high performance liquid chromatography (HPLC). Residues are suspended in 100 μL of water, and 50-μL aliquots are injected into HPLC^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Murakami E, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem. 2010 Nov 5;285(45):34337-47. [Content Brief]

[2]. Lam AM, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68. [Content Brief]

[3]. Sofia MJ, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010 Oct 14;53(19):7202-18. [Content Brief]

[4]. Zhang X, et al. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. Eur J Med Chem. 2018 Jan 1;143:1053-1065. [Content Brief]

Sofosbuvir 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	1.8888 mL	9.4438 mL	18.8875 mL	47.2188 mL
	5 mM	0.3778 mL	1.8888 mL	3.7775 mL	9.4438 mL
	10 mM	0.1889 mL	0.9444 mL	1.8888 mL	4.7219 mL
	15 mM	0.1259 mL	0.6296 mL	1.2592 mL	3.1479 mL
	20 mM	0.0944 mL	0.4722 mL	0.9444 mL	2.3609 mL
	25 mM	0.0756 mL	0.3778 mL	0.7555 mL	1.8888 mL
	30 mM	0.0630 mL	0.3148 mL	0.6296 mL	1.5740 mL
	40 mM	0.0472 mL	0.2361 mL	0.4722 mL	1.1805 mL
DMSO	50 mM	0.0378 mL	0.1889 mL	0.3778 mL	0.9444 mL
	60 mM	0.0315 mL	0.1574 mL	0.3148 mL	0.7870 mL
	80 mM	0.0236 mL	0.1180 mL	0.2361 mL	0.5902 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sofosbuvir1190307-88-0GS-7977 PSI-7977索非布韦索氟布韦GS7977GS 7977PSI7977PSI 7977PSI-7977HCVHepatitis C virusInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Sofosbuvir (Synonyms: 索非布韦; GS-7977; PSI-7977)

Customer Review

Other Forms of Sofosbuvir:

MCE 顾客使用本产品发表的 112 篇科研文献

Sofosbuvir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Sofosbuvir 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Sofosbuvir (Synonyms: 索非布韦; GS-7977; PSI-7977)

Customer Review

Other Forms of Sofosbuvir:

Sofosbuvir 相关抗体

MCE 顾客使用本产品发表的 112 篇科研文献

Sofosbuvir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Sofosbuvir 相关抗体:

摩尔计算器

稀释计算器

Sofosbuvir 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z